PROCEPT BioRobotics Corporation (PRCT)
PROCEPT BioRobotics Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in San Jose, CA, US. The stock last traded at $21.00, down 1.64% on the session, giving a market capitalisation of $1.20B. On trailing twelve-month figures it carries a trailing P/E of -10.82, a net margin of -32.5%. Its beta of 0.90 implies it has historically moved less than the broad market.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PROCEPT BioRobotics Corporation is most often compared with the following Healthcare names: